Company news

Formycon AG news in 2025

Formycon AG's news releases, calls and decks from 2025, newest first.

View company

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

December 9, 2025

Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region

December 4, 2025

Formycon Announces New Dupilumab Biosimilar Candidate

November 28, 2025

NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy

November 24, 2025

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

October 21, 2025

Formycon Invites to Conference Call on 2025 Half-year Results and Announces Participation in International Investor Conferences in the 3rd Quarter of 2025

July 30, 2025

Formycon Successfully Completes Patient Enrollment for the Clinical Development of Its Keytruda(R) Biosimilar Candidate FYB206

July 10, 2025

Ordinary Annual General Meeting of Formycon AG Approves all Proposed Resolutions by Large Majorities

June 18, 2025

Fresenius Kabi to announce the commercial launch of Otulfi™*, an approved Ustekinumab Biosimilar in Canada

May 27, 2025

Decks in 2025